Zura Bio Limited — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Figures are in U.S. dollars; financial statement amounts are in millions unless noted. Zura is a clinical-stage biotechnology company developing immunology medicines, including ZB-168, torudokimab, and ZB-106. It has no approved products and has generated no product revenue.
Financial results and liquidity
| Metric | Q2 2023 | Six months 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $28.2 million | $33.1 million |
| General and administrative expense | $5.7 million | $8.5 million |
| Net loss | $34.0 million | $43.6 million |
| Net loss attributable to Class A shareholders | $44.9 million | $54.7 million |
| Basic and diluted loss per share | $1.31 | $2.88 |
| Operating cash used | Not separately presented | $8.4 million |
There are no meaningful revenue or gross-margin comparisons because the company has no product sales. The shareholder-attributable losses include a $10.9 million deemed dividend related to a modification of the redeemable noncontrolling interest; this is not an operating expense.
At June 30, cash and cash equivalents were $112.8 million, total assets $113.3 million, and total liabilities $22.0 million. Current liabilities were $19.9 million; the $2.1 million private-placement warrant liability was non-current. The $10.0 million note payable was repaid in March, leaving no note payable at quarter-end. Shareholders’ equity was $70.4 million, alongside $20.9 million of redeemable noncontrolling interest. The company reported an accumulated deficit of $86.8 million.
Changes versus the comparable periods
- Q2 operating expenses rose to $33.9 million from $0.9 million in Q2 2022; net loss increased to $34.0 million from $0.9 million. Q2 2022 was an early-stage period, so the comparison is not on an equivalent operating scale.
- For the six months, operating expenses were $41.6 million versus $8.7 million in the 2022 inception-to-June period; net loss was $43.6 million versus $8.7 million.
- The main expense driver was the 2023 Lilly license, including approximately $27.2 million of Q2 R&D expense for acquired in-process research and development. Higher personnel, share-based compensation, public-company costs, and advisory/manufacturing expenses also contributed.
- Cash increased from $1.6 million at December 31, 2022, primarily following $56.7 million of Business Combination proceeds and approximately $79.9 million net proceeds from the April private placement.
Outlook, risks, and unusual items
- Management expects significant operating losses and negative operating cash flows to continue, with R&D and public-company costs rising. It expects current liquidity to fund operations for at least the next 12 months, but states estimates depend on assumptions and additional financing will be needed.
- No specific financial guidance was provided. Zura says it does not expect product revenue for at least the next few years and may never become profitable.
- License obligations include Pfizer development/regulatory milestones up to $70 million and sales milestones up to $525 million; Lilly licenses include development/regulatory milestones up to $155 million and sales milestones up to $440 million each where specified in the agreements. Royalties and additional contingent fees may also apply. Timing and amounts are uncertain and contingent on future events.
- The 2023 Lilly license included cash and share consideration. Related obligations include a $5 million BAFFX17 fee recorded in accrued expenses, annual Stone Peach payments beginning at $0.6 million and rising 10% annually, and further contingent payments, milestone fees, and royalties.
- The April 2023 private placement issued 15.0 million ordinary shares and pre-funded warrants for up to 3.8 million shares, creating substantial dilution. Warrants and outstanding equity awards could add further dilution; loss-per-share calculations exclude potentially dilutive securities as anti-dilutive.
- Risks include clinical and regulatory failure, need for additional capital, competition, manufacturing and development uncertainty, and substantial contingent license costs. The company also disclosed that financial-institution deposits can exceed the $250,000 federal insurance limit; its previously held Silicon Valley Bank deposits were restored after the bank’s failure.
- No material litigation or subsequent events requiring disclosure were reported. Management concluded disclosure controls were effective at a reasonable assurance level as of June 30, 2023.
Important facts for investors to verify
- Whether $112.8 million of quarter-end cash supports the planned development pace and the stated minimum 12-month runway.
- The timing, probability, and potential cash impact of clinical programs, regulatory milestones, license payments, royalties, and Stone Peach/BAFFX17 obligations.
- The precise scope and status of clinical testing: the filing describes the pipeline as clinical-stage but also states the company had not conducted clinical trials itself.
- Potential dilution from the April placement, pre-funded and other warrants, options, restricted share units, and future equity financing.
- How much future R&D spending reflects one-time license acquisition charges versus recurring development costs.